Lopresti Adrian L, Smith Stephen J, Malvi Hakeemudin, Kodgule Rahul
College of Science, Health, Engineering, and Education (SHEE), Murdoch University, Perth.
Clinical Research Australia, Duncraig, Western Australia, Australia.
Medicine (Baltimore). 2019 Sep;98(37):e17186. doi: 10.1097/MD.0000000000017186.
Ashwagandha (Withania somnifera (L.) Dunal) is a herb traditionally used to reduce stress and enhance wellbeing. The aim of this study was to investigate its anxiolytic effects on adults with self-reported high stress and to examine potential mechanisms associated with its therapeutic effects.
In this 60-day, randomized, double-blind, placebo-controlled study the stress-relieving and pharmacological activity of an ashwagandha extract was investigated in stressed, healthy adults. Sixty adults were randomly allocated to take either a placebo or 240 mg of a standardized ashwagandha extract (Shoden) once daily. Outcomes were measured using the Hamilton Anxiety Rating Scale (HAM-A), Depression, Anxiety, and Stress Scale -21 (DASS-21), and hormonal changes in cortisol, dehydroepiandrosterone-sulphate (DHEA-S), and testosterone.
All participants completed the trial with no adverse events reported. In comparison with the placebo, ashwagandha supplementation was associated with a statistically significant reduction in the HAM-A (P = .040) and a near-significant reduction in the DASS-21 (P = .096). Ashwagandha intake was also associated with greater reductions in morning cortisol (P < .001), and DHEA-S (P = .004) compared with the placebo. Testosterone levels increased in males (P = .038) but not females (P = .989) over time, although this change was not statistically significant compared with the placebo (P = .158).
These findings suggest that ashwagandha's stress-relieving effects may occur via its moderating effect on the hypothalamus-pituitary-adrenal axis. However, further investigation utilizing larger sample sizes, diverse clinical and cultural populations, and varying treatment dosages are needed to substantiate these findings.
Clinical Trials Registry-India (CTRI registration number: CTRI/2017/08/009449; date of registration 22/08/2017).
南非醉茄(Withania somnifera (L.) Dunal)是一种传统上用于减轻压力和增进幸福感的草药。本研究的目的是调查其对自我报告有高压力的成年人的抗焦虑作用,并研究与其治疗效果相关的潜在机制。
在这项为期60天的随机、双盲、安慰剂对照研究中,对压力大的健康成年人研究了南非醉茄提取物的减压和药理活性。60名成年人被随机分配,每天服用一次安慰剂或240毫克标准化南非醉茄提取物(Shoden)。使用汉密尔顿焦虑评定量表(HAM - A)、抑郁、焦虑和压力量表 - 21(DASS - 21)以及皮质醇、硫酸脱氢表雄酮(DHEA - S)和睾酮的激素变化来测量结果。
所有参与者均完成试验,未报告不良事件。与安慰剂相比,补充南非醉茄与HAM - A评分有统计学意义的降低相关(P = 0.040),DASS - 21评分接近显著降低(P = 0.096)。与安慰剂相比,服用南非醉茄还与早晨皮质醇(P < 0.001)和DHEA - S(P = 0.004)的更大降低相关。随着时间推移,男性睾酮水平升高(P = 0.038),女性则未升高(P = 0.989),尽管与安慰剂相比这种变化无统计学意义(P = 0.158)。
这些发现表明,南非醉茄的减压作用可能通过其对下丘脑 - 垂体 - 肾上腺轴的调节作用而发生。然而,需要利用更大样本量、不同临床和文化人群以及不同治疗剂量进行进一步研究,以证实这些发现。
印度临床试验注册中心(CTRI注册号:CTRI/2017/08/009449;注册日期2017年8月22日)。